
Opinion|Videos|June 26, 2024
Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.
Advertisement
Episodes in this series

- Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
- What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (
Logan Cancers 2023 ,Kumaraswamy JCI Insight 2023 , please highlight any others)
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
4
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
5

